Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCAREPVTLTDADA8 65b0b7e3912bef38d51b547d Medicines https://www.sterispharma.com
ST-GLIPTIN M50/1000
ST-GLIPTIN M50/1000
In Stock
Diabetic Range by Sitagliptin (50mg), Metformin SR 1000

ST-GLIPTIN M50/1000

INR 399 INR 570
You Save: INR 171 (30%)
In Stock
COD available
COD available

Description

Product details

ST-GLIPTIN M50/1000 Sitagliptin (50mg), Metformin SR 1000 Introduction: Diabetes mellitus is a complex metabolic disorder that requires multifaceted treatment strategies to achieve optimal glycemic control and reduce the risk of complications. Sitagliptin and metformin are two widely used medications in the management of type 2 diabetes mellitus (T2DM), each with distinct mechanisms of action. ST-GLIPTIN M50/1000, a fixed-dose combination tablet containing sitagliptin (50mg) and extended-release metformin (1000mg), offers a synergistic approach to diabetes care. This article explores the features, efficacy, safety profile, and clinical implications of ST-GLIPTIN M50/1000 in the treatment of T2DM. Understanding Sitagliptin and Metformin SR: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and decreases glucagon levels in a glucose-dependent manner, thereby improving glycemic control. Metformin, on the other hand, is a biguanide medication that primarily reduces hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity. The extended-release formulation of metformin allows for once-daily dosing and may reduce gastrointestinal side effects compared to immediate-release formulations. Key Features of ST-GLIPTIN M50/1000: ST-GLIPTIN M50/1000 is a fixed-dose combination tablet containing sitagliptin (50mg) and extended-release metformin (1000mg) in a standardized formulation. This combination offers the convenience of administering two effective antidiabetic agents in a single tablet, simplifying medication regimens and enhancing patient adherence. The complementary mechanisms of action of sitagliptin and metformin SR provide comprehensive glycemic control, addressing both fasting and postprandial hyperglycemia. Efficacy in Glycemic Control: Clinical studies have demonstrated the efficacy of ST-GLIPTIN M50/1000 in improving glycemic control in patients with T2DM. The combination of sitagliptin and metformin SR has been shown to reduce hemoglobin A1c (HbA1c) levels, fasting plasma glucose, and postprandial glucose excursions, leading to improvements in overall glucose regulation. Additionally, the extended-release formulation of metformin may offer advantages in terms of tolerability and gastrointestinal side effects compared to immediate-release formulations. Safety Profile: ST-GLIPTIN M50/1000 exhibits a favorable safety profile, with adverse effects typically mild to moderate in severity. Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, or abdominal discomfort, which are often transient and diminish with continued use. Serious adverse events with ST-GLIPTIN M50/1000 are rare, and it is generally well-tolerated by most patients. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP:: 7877551268, 8209542042, 8955945010, 6377716668 https://www.sterisonline.com/product/st-gliptin-m50-1000-134014

  • Filter tags

Have any question or need any business consultation?

Have any question or need any business consultation?

Contact Us
Chat with us